Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
05/2003
05/15/2003WO2003039446A2 Use of 2-amino-4-pyridylmethyl-thiazoline derivatives as inhibitors of inducible no-synthase
05/15/2003WO2003039444A2 Topical use of cytokines and/or chemokines for the treatment of viral or mykotic skin diseases or tumoral diseases
05/15/2003WO2003039418A1 Compositions for the treatment of infectious diseases
05/15/2003WO2003020754A3 Inhibition of replication factor c
05/15/2003WO2003004509A3 C12 modified erythromycin macrolides and ketolides having antibacterial activity
05/15/2003WO2002083926A3 Methods of diagnosing and treating small intestinal bacterial overgrowth (sibo) and sibo-related conditions
05/15/2003WO2002068637A8 Nucleic acid-based treatment of diseases or conditions related to west nile virus infection
05/15/2003WO2002067961A3 Therapeutic uses of herbal compositions
05/15/2003WO2002059156A3 Therapeutic compounds structurally-linked to bacterial polypeptides
05/15/2003WO2002057298A3 C-terminal modified oxamyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases
05/15/2003WO2002055108A9 Targeted modification of intracellular compounds
05/15/2003WO2002040016A8 Association of calpain inhibitors and reactive oxygen species trapping agents
05/15/2003WO2002038181A3 Synergistic medicament containing aromatic agents and having an antagonistic, regenerative and/or protagonist decontamination effect
05/15/2003WO2002030392A3 Formulation containing amoxicillin
05/15/2003WO2002026781A9 Ige receptor antagonists
05/15/2003WO2002026717A8 Hydroxy acid integrin antagonists
05/15/2003WO2001071309A3 Methods and reagents for regulation of cellular responses in biological systems
05/15/2003US20030092897 Antigen composition against mycoplasma
05/15/2003US20030092894 Conjugated antigen for use as tool in the treatment of cancer
05/15/2003US20030092771 Inhibitors of transcription factor NF-kappaB
05/15/2003US20030092764 Oxidation resistance
05/15/2003US20030092762 Anti-inflammatory nitro and thia-fatty acids
05/15/2003US20030092755 Novel prodrugs for antimicrobial amidines
05/15/2003US20030092748 Benzenesulfonamide derivatives and their use as MEK inhibitors
05/15/2003US20030092743 Viricides; aids therapy
05/15/2003US20030092732 Eating disorders; dietetics; antiinflammatory agents; autoimmune diseases
05/15/2003US20030092729 Anticancer agents; modulating glycoprotein
05/15/2003US20030092727 Hydroxamic and carboxylic acid derivatives
05/15/2003US20030092718 4-amino-2-(2-pyridyl)pyrimidines as microbicidal active substances
05/15/2003US20030092717 Inhibitors of p38 kinase
05/15/2003US20030092714 Heterocyclic inhibitors of ERK2 and uses thereof
05/15/2003US20030092712 Antiinflammatory agents; rheumatic diseases
05/15/2003US20030092709 6-Methylnicotinamide derivatives as antiviral agents
05/15/2003US20030092703 Caspase inhibitors and uses thereof
05/15/2003US20030092702 Antiinflammatory agents; autoimmune disease; autoimmune diseases
05/15/2003US20030092696 7-Alkylidene-3-substituted-3-cephem-4-carboxylates as beta-lactamase inhibitors
05/15/2003US20030092644 1-( beta -L-ribofuranosyl)-1,2,4-triazole-3-carboxamide as animmunomodulator; viricides
05/15/2003US20030092642 Diphosphate salt of a 4" -substituted-9-deoxo-9A-AZA-9A-homoerythromycin derivative and its pharmaceutical composition
05/15/2003US20030092640 Water, azalide compound, 25-75% propylene glycol, and acids
05/15/2003US20030092180 Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo
05/15/2003US20030092177 Preparing preferential cells from mononucler cells in culture; obtain monocytes, incubate with interferon, recover preferental cells
05/15/2003US20030092163 Probiotic bifidobacterium strains
05/15/2003US20030092130 DNA encoding polypeptides having interferon-gamma inducing activity
05/15/2003US20030092059 Human antibodies that bind human TNFalpha
05/15/2003US20030092054 Protein complexes and assays for screening anti-cancer agents
05/15/2003US20030092044 Nucleotide sequences coding polypeptide for use in the treatment of apoptosis, inflammatory and autoimmune disorders
05/15/2003US20030091987 Materials and methods for detecting, preventing, and treating retroviral infection
05/15/2003US20030091985 Cloned DNA sequences related to the entire genomic RNA of human immunodeficiency virus II (HIV-2), polypeptides encoded by these DNA sequences and use of these DNA clones and polypeptides in diagnostic kits
05/15/2003US20030091974 Detecting compounds capable of exhausting mast cells; culture mast cells, incubate with modulator, measure mast cell death, classify compound
05/15/2003US20030091667 Clear, colorless solution; mixture of surfactant and microbiocide
05/15/2003US20030091658 Herbal pharmaceutical composition for treatment of HIV/AIDS patients
05/15/2003US20030091654 Dietetics, antidiabetic agents; using chromium complex
05/15/2003US20030091653 Powders having contact biocidal properties
05/15/2003US20030091644 Low concentration of peroxide for treating or preventing vaginal infections
05/15/2003US20030091637 Drug core with polymeric overcoating
05/15/2003US20030091620 Transdermal drug delivery systems containing quaternary ammonium salts and methods of using the same
05/15/2003US20030091594 CD4-independent HIV envelope proteins as vaccines and therapeutics
05/15/2003US20030091593 In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
05/15/2003US20030091589 Veterinary medicine; feeding yeast cells
05/15/2003US20030091586 Fish immunoglobulin
05/15/2003US20030091582 Autoimmune diseases; antitumor agents; antiallergens
05/15/2003US20030091573 Methods and compositions for the diagnosis and treatment of hematological disorders using 16319
05/15/2003US20030091571 Methods and compositions for the diagnosis and treatment of hematological disorders using 2777
05/15/2003US20030091555 Sterilizing food poison bacteria using ethylenediamine, or salt thereof as chelate compound
05/15/2003US20030091549 Antiinflammatory agents; inflammatory bowel disease; gastrointestinal disorders
05/15/2003US20030091540 Uniform spreading into body cavities
05/15/2003US20030091537 Anticancer agents; gene coding immunomoderator cytokine protein
05/15/2003US20030091518 Mixture containing plant extracts and oils
05/15/2003US20030091510 Administering fungicide to mucous membrane
05/15/2003CA2789407A1 Inhibitor oligonucleotides and their use for specific repression of a gene
05/15/2003CA2669810A1 2-amino-thiazoline derivatives and their use as inhibitors of inducible no-synthase
05/15/2003CA2474196A1 Topical use of cytokines and/or chemokines for the treatment of viral or mykotic skin diseases or tumoral diseases
05/15/2003CA2467853A1 Antibody stimulating il-1ra production
05/15/2003CA2466334A1 Methods for inhibiting proliferation of astrocytes and astrocytic tumor cells and for enhancing survival of neurons and uses thereof
05/15/2003CA2466198A1 Somatic cell derived embryonic stem cells and their differentiated progenies
05/15/2003CA2466145A1 Novel 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators
05/15/2003CA2466083A1 Compositions for the treatment of infectious diseases
05/15/2003CA2466030A1 Intraorally disintegrating valdecoxib compositions prepared by fluid bed granulation process
05/15/2003CA2465756A1 Compositions containing oils having a specific gravity higher than the specific gravity of water
05/15/2003CA2465753A1 Orodispersible tablet having high homogeneity and the preparation method thereof
05/15/2003CA2465731A1 Screening for hepatitis c virus entry inhibitors
05/15/2003CA2465711A1 Aminopyrimidines and pyridines
05/15/2003CA2465695A1 2-amino-thiazoline derivatives and their use as inhibitors of inducible no-synthase
05/15/2003CA2465679A1 High level constitutive production of anthrax protective antigen
05/15/2003CA2465420A1 Anhydrous crystal form of valaciclovir hydrochloride
05/15/2003CA2465364A1 Pharmaceutical composition comprising an adenosine a1/a2 agonist and a sodium hydrogen exchanger inhibitor
05/15/2003CA2465239A1 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
05/15/2003CA2465189A1 Substituted diphenyl heterocycles useful for treating hcv infection
05/15/2003CA2465159A1 Process for preparing quick dissolving, high loading ribavirin compositions
05/15/2003CA2464763A1 5-amidino-2-hydroxybenzenesulfonamide derivatives, medicinal compositions containing the same, medicinal use thereof and intermediates in the production thereof
05/15/2003CA2464757A1 Selective antibacterial agents
05/14/2003EP1310558A2 Stable bactericidal/permeability-increasing protein products and pharmaceutical compositions containing the same
05/14/2003EP1310552A2 Posh nucleic acids, polypeptides and related methods
05/14/2003EP1310551A1 Virus-like micrograins and process for producing the same
05/14/2003EP1310507A2 Novel peptide nucleic acids
05/14/2003EP1310502A1 Phosphonocephem compound
05/14/2003EP1310498A2 Pyrazoloquinolinone derivatives as protein kinase C inhibitors
05/14/2003EP1310495A2 Glycidyl amines and their use in the preparation of HIV protease inhibitors
05/14/2003EP1310493A1 N-adamantylalkyl benzamide derivates as p2x7-receptor antagonists
05/14/2003EP1310491A1 Method for producing 1-substituted-1,2,3-triazole derivative
1 ... 1187 1188 1189 1190 1191 1192 1193 1194 1195 1196 1197 1198 1199 1200 1201 1202 1203 1204 1205 1206 1207 ... 1798